Ignacio
Gil Bazo
Chercheur jusqu' 2022
University of Texas MD Anderson Cancer Center
Houston, Estados UnidosPublications en collaboration avec des chercheurs de University of Texas MD Anderson Cancer Center (9)
2022
-
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations
JCO global oncology, Vol. 8, pp. e2200123
2020
-
Precision prevention and cancer interception: The new challenges of liquid biopsy
Cancer Discovery, Vol. 10, Núm. 11, pp. 1635-1644
2019
-
5 protein-based signature for resectable lung squamous cell carcinoma improves the prognostic performance of the TNM staging
Thorax, Vol. 74, Núm. 4, pp. 371-379
-
Inhibitor of differentiation-1 sustains mutant KRAS-driven progression, maintenance, and metastasis of lung adenocarcinoma via regulation of a FOSL1 network
Cancer Research, Vol. 79, Núm. 3, pp. 625-638
-
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib
American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899
2015
-
Corrigendum to "Liquid biopsies in lung cancer: The new ambrosia of researchers" [Biochem. Biophys. Act. 1846(2014) 539-546]
Biochimica et Biophysica Acta - Reviews on Cancer
2014
-
Liquid biopsies in lung cancer: The new ambrosia of researchers
Biochimica et Biophysica Acta - Reviews on Cancer, Vol. 1846, Núm. 2, pp. 539-546
-
Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors
Cancer Treatment Reviews, Vol. 40, Núm. 8, pp. 990-1004
2011
-
Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance
Clinical Cancer Research, Vol. 17, Núm. 12, pp. 4155-4166